Wednesday, May 27, 2015

Seeking Alpha: All Is Well With Neurocrine Biosciences, And It Could Get Better

With the company's analyst day behind it, Neurocrine Biosciences (NASDAQ:NBIX) is looking well. This biotech could have two approved drugs in hand within a couple of years that each generate more than $1 billion in sales (at peak), plus a third drug with solid potential as an orphan indication. Better still, I don't believe it takes particularly robust expectations to generate an attractive fair value for the stock and significant trial data read-outs this year could unlock significant value if the data are positive.

Click here for the full article:
All Is Well With Neurocrine Biosciences, And It Could Get Better

No comments: